Risk of business disruption due to the spread of COVID-19
First written in FY2020. 7 of 12 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024RestatedAnnual report
「However, if a large-scale infectious disease spreads in the future and disrupts the supply of products and merchandise or research and development activities, our Group's operating results and financial position may be affected by business stagnation and other factors.」
The business disruption risk has been reaffirmed as applying generally to large-scale infectious diseases, rather than specifically to COVID-19. - FY2023ReframedAnnual report
「If a large-scale infectious disease spreads in the future and disrupts the supply of products and merchandise or research and development activities, our Group's operating results and financial position may be affected by business stagnation and other factors.」
The risk has been reframed from the previous description focused on COVID-19 as a general risk of future large-scale infectious diseases and new pandemics. - FY2023-Q3RestatedAnnual report
「Regarding the impact of COVID-19 on our business and results, we expect certain activity restrictions to remain in place, but expect the impact on operating profit to be minor.」
The explanation has been reaffirmed that certain activity restrictions are expected to remain in place, while the impact of COVID-19 on operating profit is expected to be minor. - FY2023-Q2RestatedAnnual report
「Regarding the impact of COVID-19 on our business and results, we expect certain activity restrictions to remain in place, but expect the impact on operating profit to be minor.」
The explanation has been reaffirmed that certain activity restrictions are expected to remain in place, while the impact of COVID-19 on operating profit is expected to be minor. - FY2023-Q1RestatedAnnual report
「Regarding the impact of COVID-19 on our business and results, we expect certain activity restrictions to remain in place, but expect the impact on operating profit to be minor.」
The explanation has been reaffirmed that certain activity restrictions are expected to remain in place, while the impact of COVID-19 on operating profit is expected to be minor. - FY2022RestatedAnnual report
「The impact of the spread of COVID-19 on results for the fiscal year was minor, but we will continue to monitor developments because our results could be affected if the situation persists or worsens in the future.」
Although the impact on results for the year was described as minor, the potential impact of a prolonged or worsening spread of infection continues to be disclosed. - FY2022-Q3RestatedAnnual report
「Regarding the impact of COVID-19 on our business and results, we expect certain activity restrictions to remain in place, but expect the impact on operating profit to be minor.」
The explanation has been reaffirmed that certain activity restrictions are expected to remain in place, while the impact on operating profit is expected to remain minor. - FY2022-Q1RestatedAnnual report
「Regarding the impact of COVID-19 on our business and results, we expect certain activity restrictions to remain in place, but continue to expect the impact on operating profit to be minor.」
The explanation has been reaffirmed that certain activity restrictions are expected to remain in place, while the impact on operating profit is expected to remain minor. - FY2021MitigatedAnnual report
「Since June last year, we have gradually begun resuming sales activities, starting in regions and at medical institutions less affected, and have pursued information-provision activities using new methods in addition to conventional visits, including web-based meetings and planning remote lectures. The impact of the spread of COVID-19 on results for the fiscal year included delays in starting new clinical trials, suspensions of ongoing clinical trials and restrictions on MR visits to medical institutions, but the impact on operating profit was minor.」
Although clinical trials were postponed or suspended and visits were restricted, sales activities were gradually resumed using digital methods alongside conventional activities. The impact on full-year operating profit was described as minor. - FY2021-Q2MaterialisedAnnual report
「Research and development expenses decreased by ¥5,200 million, or 16.8%, year on year to ¥25,700 million. Although development activities, including subject registration, resumed from June, clinical trial costs declined due to delays in starting subject registration for new clinical trials and the suspension of subject registration in ongoing trials as a result of the impact of COVID-19. Selling, general and administrative expenses excluding research and development expenses decreased by ¥3,900 million, or 11.6%, year on year to ¥29,800 million, as operating activity expenses declined due to the review of academic conferences and restrictions on MR visits to medical institutions resulting from the impact of COVID-19.」
The postponement and suspension of clinical trial subject registration, the review of academic conferences and restrictions on MR visits due to the impact of COVID-19 were reflected in the cumulative second-quarter results as decreases in research and development expenses and selling, general and administrative expenses. Meanwhile, development activities resumed from June. - FY2021-Q1MitigatedAnnual report
「As a life sciences company, our Group is working with affiliated companies and business partners to ensure a stable supply of pharmaceuticals, and there are currently no issues with the production of our pharmaceuticals or their supply to medical institutions. To protect the safety and health of patients, healthcare professionals and employees and prevent the spread of infection, we had refrained from visiting medical institutions. Following the lifting of the state of emergency, however, we have gradually resumed development activities, including the registration of clinical trial subjects, since June.」
There were no issues with the production or supply of pharmaceuticals, and development activities that had been suspended were gradually resumed from June. Although a slight negative impact on sales from July onward is expected, the impact on operating profit is estimated to be minor. - FY2020MaterialisedAnnual report
「As a life sciences company, our Group is working with affiliated companies and business partners to ensure a stable supply of pharmaceuticals, and is maintaining that supply. There are currently no issues with the production of our pharmaceuticals or their supply to medical institutions.」
The spread of COVID-19 was identified for the first time as a separate major risk, with restrictions on visits to medical institutions, event cancellations and postponements, and the potential disruption of research and development and supply indicated.